Key result
Serum tenascin-C levels were higher in patients with ventricular noncompaction/hypertrabeculation compared to normal controls.
Why the study?
Are serum tenascin-C levels elevated in adult patients with ventricular noncompaction/hypertrabeculation compared to normal controls?
Cross-Sectional (n=73)
Are serum tenascin-C levels elevated in adult patients with ventricular noncompaction/hypertrabeculation compared to normal controls?
Serum tenascin-C is significantly elevated in adult patients with ventricular noncompaction/hypertrabeculation regardless of systolic function, suggesting its potential as a diagnostic biomarker.
Answers are grounded in this paper and cite their sources.
Tenascin-C elevation was associated with ventricular noncompaction; hypothesis-generating for diagnostic biomarker utility and requires prospective validation.
PURPOSE: Ventricular noncompaction/hypertrabeculation (NC/HT) is a rare form of congenital cardiomyopathy. We aimed to investigate the presence of serum tenascin-C (TN-C) in adult patients with NC/HT and evaluate its value. METHODS AND RESULTS: Serum TN-C levels were measured by ELISA in 50 NC/HT patients both with/without systolic dysfunction and in 23 normal controls. Systolic dysfunction was defined as ejection fraction (EF) ≤ 40. Mann-Whitney U-test and ROC curve analysis were done. Of 49 NC/HT patients, 24 (49%) patients had systolic dysfunction (mean age 36 ± 15) and 25 patients (51%) had normal systolic function (mean age 36 ± 17). The ages between groups were not different. The mean levels of serum TN-C in patients with or without systolic dysfunction were 26 ± 10 ng/mL and 26 ± 8 ng/mL respectively, compared to normal controls, 7 ± 2 ng/mL (P < 0.001). No significance was observed between 2 groups of NC/HT patients regarding TN-C levels (P = 0.8). The ROC curve analysis revealed that a TN-C value of 11.7 ng/mL identified patients with NC/HT with 100% sensitivity and specifity. CONCLUSION: High serum TN-C levels are present in adult NC/HT cardiomyopathy even when left ventricular systolic function remains normal. Also, serum TN-C levels could be regarded as a candidate biomarker in the diagnosis of NC/HT which needs to be tested in larger prospective studies.
No takes yet. Share an insight, caveat, or question.
Erer et al. (2013) conducted a cross-sectional in Ventricular noncompaction/hypertrabeculation (NC/HT) (n=73). Ventricular noncompaction/hypertrabeculation (NC/HT) vs. Normal controls was evaluated on Serum TN-C levels (ng/mL) (p=<0.001). Serum tenascin-C levels were higher in patients with ventricular noncompaction/hypertrabeculation compared to normal controls.
Synapse has enriched 10 related papers. Consider them for comparative context: